These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32012202)

  • 41. Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients.
    Wu Q; Wang Q; Mao G; Dowling CA; Lundy SK; Mao-Draayer Y
    J Immunol; 2017 Apr; 198(8):3069-3080. PubMed ID: 28258191
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia.
    Malone K; Diaz Diaz AC; Shearer JA; Moore AC; Waeber C
    J Neuroinflammation; 2021 Jan; 18(1):37. PubMed ID: 33516262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation.
    Karnell FG; Lin D; Motley S; Duhen T; Lim N; Campbell DJ; Turka LA; Maecker HT; Harris KM
    Clin Exp Immunol; 2017 Sep; 189(3):268-278. PubMed ID: 28498568
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients.
    Traub JW; Pellkofer HL; Grondey K; Seeger I; Rowold C; Brück W; Husseini L; Häusser-Kinzel S; Weber MS
    J Neuroinflammation; 2019 Nov; 16(1):228. PubMed ID: 31733652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
    De Stefano N; Tomic D; Radue EW; Sprenger T; Meier DP; Häring D; Sormani MP
    Mult Scler Relat Disord; 2016 May; 7():98-101. PubMed ID: 27237768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
    J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy.
    Fujii C; Kondo T; Ochi H; Okada Y; Hashi Y; Adachi T; Shin-Ya M; Matsumoto S; Takahashi R; Nakagawa M; Mizuno T
    Sci Rep; 2016 Oct; 6():35314. PubMed ID: 27752051
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circulating lymphocyte and T memory subsets in glucocorticosteroid versus IVIG treated patients with CIDP.
    Klehmet J; Staudt M; Ulm L; Unterwalder N; Meisel A; Meisel C
    J Neuroimmunol; 2015 Jun; 283():17-22. PubMed ID: 26004151
    [TBL] [Abstract][Full Text] [Related]  

  • 49. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients.
    Lovett-Racke AE; Gormley M; Liu Y; Yang Y; Graham C; Wray S; Racke MK; Shubin R; Twyman C; Alvarez E; Bass A; Eubanks JL; Fox E
    J Neuroimmunol; 2019 Jul; 332():187-197. PubMed ID: 31077854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ASP0028 in combination with suboptimal-dose of tacrolimus in Cynomolgus monkey renal transplantation model.
    Dun H; Song L; Ma A; Hu Y; Zeng L; Bai J; Zhang G; Zhang L; Koide K; Okada Y; Hanaoka K; Yamamoto R; Hirose J; Morokata T; Daloze P; Chen H
    Transpl Immunol; 2017 Feb; 40():57-65. PubMed ID: 28077266
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.
    Fragoso YD; Spelman T; Boz C; Alroughani R; Lugaresi A; Vucic S; Butzkueven H; Terzi M; Havrdova E; Horakova D; Granella F; Olascoaga J; Sánchez-Menoyo JL; Pucci E; Barnett M; Brooks JBB; Haartsen J;
    Mult Scler Relat Disord; 2018 Jan; 19():105-108. PubMed ID: 29182993
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.
    Henault D; Galleguillos L; Moore C; Johnson T; Bar-Or A; Antel J
    Neurology; 2013 Nov; 81(20):1768-72. PubMed ID: 24132373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Peripheral CD39-expressing T regulatory cells are increased and associated with relapsing-remitting multiple sclerosis in relapsing patients.
    Álvarez-Sánchez N; Cruz-Chamorro I; Díaz-Sánchez M; Lardone PJ; Guerrero JM; Carrillo-Vico A
    Sci Rep; 2019 Feb; 9(1):2302. PubMed ID: 30783191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report.
    Lovett-Racke AE; Yang Y; Liu Y; Gormley M; Kraus E; Graham C; Wray S; Racke MK; Alvarez E; Bass A; Fox E
    J Neuroimmunol; 2021 Oct; 359():577676. PubMed ID: 34364105
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recognition of viral and self-antigens by T
    Paroni M; Maltese V; De Simone M; Ranzani V; Larghi P; Fenoglio C; Pietroboni AM; De Riz MA; Crosti MC; Maglie S; Moro M; Caprioli F; Rossi R; Rossetti G; Galimberti D; Pagani M; Scarpini E; Abrignani S; Geginat J
    J Allergy Clin Immunol; 2017 Sep; 140(3):797-808. PubMed ID: 28237728
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
    Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
    CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FTY720 treatment of kidney transplant patients: a differential effect on B cells, naïve T cells, memory T cells and NK cells.
    Vaessen LM; van Besouw NM; Mol WM; Ijzermans JN; Weimar W
    Transpl Immunol; 2006 Apr; 15(4):281-8. PubMed ID: 16635750
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8
    Abbadessa G; Lepore MT; Bruzzaniti S; Piemonte E; Miele G; Signoriello E; Perna F; De Falco C; Lus G; Matarese G; Bonavita S; Galgani M
    Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200250. PubMed ID: 38662990
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationships of total leukocyte, neutrophil and lymphocyte levels with the menstrual cycle in patients receiving fingolimod treatment.
    Ekmekyapar T; Ozcan C; Ciftci O
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):447-454. PubMed ID: 33506935
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients.
    Hovi A; Airas L
    J Neuroimmune Pharmacol; 2016 Dec; 11(4):611-612. PubMed ID: 27388874
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.